AstraZeneca's cancer drug fails to meet main goal in COVID-19 trials

AstraZeneca Plc said on Thursday its blood cancer treatment, Calquence, failed to meet the main goal of mid-stage trials, testing it in patients hospitalized with respiratory symptoms of COVID-19.

The drugmaker called the results from the study disappointing but said it remained committed to its clinical trials for its COVID-19 vaccine, developed in partnership with Oxford University, and its long-acting antibody combination.

Results from the trials will not impact approved indications or pending approvals for Calquence in patients with blood cancers, the company said.